Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Smoking Affects the Predictive Roles of Antioxidant Enzymes in the Clinical Response to Risperidone in Schizophrenia: A Large-scale Cohort Study

Author(s): Meihong Xiu, Xiuli Song, Hanlun Yang, Xingjuan Huang, Fengchun Wu* and Xiangyang Zhang*

Volume 21, Issue 10, 2023

Published on: 03 May, 2023

Page: [2151 - 2158] Pages: 8

DOI: 10.2174/1570159X21666230502125800

Price: $65

Abstract

Objectives: There is overwhelming evidence of the relationship between smoking and schizophrenia (SZ). Tobacco smoke is considered to ameliorate the symptoms and reduce the side effects of antipsychotics in SZ patients. However, the underlying biological mechanism by which tobacco smoke improves symptoms in SZ remains unclear. This study was designed to examine the effects of tobacco smoke on antioxidant enzyme activities and psychiatric symptoms after receiving 12-week risperidone monotherapy.

Methods: Two hundred and fifteen antipsychotic-naïve first-episode (ANFE) patients were recruited and treated with risperidone for 3 months. The severity of the patient’s symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS) at baseline and at post-treatment. Plasma SOD, GSH-Px, and CAT activities were determined at baseline and follow-up.

Results: Relative to nonsmoking patients with ANFE SZ, patients who smoked had higher baseline CAT activity. In addition, among non-smokers with SZ, baseline GSH-Px was associated with clinical symptom improvement, while baseline CAT was associated with positive symptom improvement in smokers with SZ.

Conclusion: Our findings demonstrate that smoking affects the predictive role of baseline SOD, GSHPx, and CAT activities on clinical symptom improvement in patients with SZ.

« Previous Next »
Graphical Abstract

[1]
Myles, N.; Newall, H.D.; Curtis, J.; Nielssen, O.; Shiers, D.; Large, M. Tobacco use before, at, and after first-episode psychosis: A systematic meta-analysis. J. Clin. Psychiatry, 2012, 73(4), 468-475.
[http://dx.doi.org/10.4088/JCP.11r07222] [PMID: 22579146]
[2]
Winterer, G. Why do patients with schizophrenia smoke? Curr. Opin. Psychiatry, 2010, 23(2), 112-119.
[http://dx.doi.org/10.1097/YCO.0b013e3283366643] [PMID: 20051860]
[3]
Lawrence, D.; Mitrou, F.; Zubrick, S.R. Smoking and mental illness: Results from population surveys in Australia and the United States. BMC Public Health, 2009, 9(1), 285.
[http://dx.doi.org/10.1186/1471-2458-9-285] [PMID: 19664203]
[4]
Williams, J.; Ziedonis, D.; Abanyie, F.; Steinberg, M.; Foulds, J.; Benowitz, N. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr. Res., 2005, 79(2-3), 323-335.
[http://dx.doi.org/10.1016/j.schres.2005.04.016] [PMID: 15961287]
[5]
Šagud, M.; Vuksan-Ćusa, B.; Jakšić, N.; Mihaljević-Peleš, A.; Živković, M.; Vlatković, S.; Prgić, T.; Marčinko, D.; Wang, W. Nicotine dependence in Croatian male inpatients with schizophrenia. BMC Psychiatry, 2018, 18(1), 18.
[http://dx.doi.org/10.1186/s12888-018-1606-1] [PMID: 29357830]
[6]
Stolz, P.A.; Wehring, H.J.; Liu, F.; Love, R.C.; Ellis, M.; DiPaula, B.A.; Kelly, D.L. Effects of cigarette smoking and clozapine treatment on 20-year all-cause & cardiovascular mortality in Schizophrenia. Psychiatr. Q., 2019, 90(2), 351-359.
[http://dx.doi.org/10.1007/s11126-018-9621-4] [PMID: 30632082]
[7]
Montuschi, P.; Collins, J.; Ciabattoni, G.; Lazzeri, N.; Corradi, M.; Kharitonov, S.A.; Barnes, P.J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med., 2000, 162(3), 1175-1177.
[http://dx.doi.org/10.1164/ajrccm.162.3.2001063] [PMID: 10988150]
[8]
James, R.W.; Leviev, I.; Righetti, A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation, 2000, 101(19), 2252-2257.
[http://dx.doi.org/10.1161/01.CIR.101.19.2252] [PMID: 10811591]
[9]
Grabnar, I.; Vovk, T.; Kores Plesničar, B.; Boskovic, M. Oxidative stress in schizophrenia. Curr. Neuropharmacol., 2011, 9(2), 301-312.
[http://dx.doi.org/10.2174/157015911795596595] [PMID: 22131939]
[10]
Ahmadi-Motamayel, F.; Falsafi, P.; Goodarzi, M.T.; Poorolajal, J. Evaluation of salivary catalase, vitamin C, and alpha-amylase in smokers and non-smokers: A retrospective cohort study. J. Oral Pathol. Med., 2017, 46(5), 377-380.
[http://dx.doi.org/10.1111/jop.12495] [PMID: 27800633]
[11]
Changeux, J.P. Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat. Rev. Neurosci., 2010, 11(6), 389-401.
[http://dx.doi.org/10.1038/nrn2849] [PMID: 20485364]
[12]
Dome, P.; Lazary, J.; Kalapos, M.P.; Rihmer, Z. Smoking, nicotine and neuropsychiatric disorders. Neurosci. Biobehav. Rev., 2010, 34(3), 295-342.
[http://dx.doi.org/10.1016/j.neubiorev.2009.07.013] [PMID: 19665479]
[13]
Guan, Z.; Yu, W.F.; Nordberg, A. Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. Neurochem. Int., 2003, 43(3), 243-249.
[http://dx.doi.org/10.1016/S0197-0186(03)00009-3] [PMID: 12689604]
[14]
MacNEE, W.I.L.L.I.A.M.; Rahman, I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1999, 160(5 Pt 2), S58-S65.
[http://dx.doi.org/10.1164/ajrccm.160.supplement_1.15] [PMID: 10556172]
[15]
Cecerska-Heryć, E.; Polikowska, A.; Serwin, N.; Roszak, M.; Grygorcewicz, B.; Heryć, R.; Michalczyk, A.; Dołęgowska, B. Importance of oxidative stress in the pathogenesis, diagnosis, and monitoring of patients with neuropsychiatric disorders, a review. Neurochem. Int., 2022, 153, 105269.
[http://dx.doi.org/10.1016/j.neuint.2021.105269] [PMID: 34971747]
[16]
Murray, A.J.; Rogers, J.C.; Katshu, M.Z.U.H.; Liddle, P.F.; Upthegrove, R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front. Psychiatry, 2021, 12, 703452.
[http://dx.doi.org/10.3389/fpsyt.2021.703452] [PMID: 34366935]
[17]
Liu, H.; Yu, R.; Gao, Y.; Li, X.; Guan, X.; Thomas, K.; Xiu, M.; Zhang, X. Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: A prospective longitudinal study. Curr. Neuropharmacol., 2022, 20(9), 1774-1782.
[PMID: 34544343]
[18]
Li, X.R.; Xiu, M.H.; Guan, X.N.; Wang, Y.C.; Wang, J.; Leung, E.; Zhang, X.Y. Altered antioxidant defenses in drug-naive first episode patients with schizophrenia are associated with poor treatment response to risperidone: 12-week results from a prospective longitudinal study. Neurotherapeutics, 2021, 18(2), 1316-1324.
[http://dx.doi.org/10.1007/s13311-021-01036-3] [PMID: 33791970]
[19]
Xiu, M.H.; Li, Z.; Chen, D.C.; Chen, S.; Curbo, M.E.; Wu, H.E.; Tong, Y.S.; Tan, S.P.; Zhang, X.Y. Interrelationships between BDNF, superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with schizophrenia. Schizophr. Bull., 2020, 46(6), 1498-1510.
[http://dx.doi.org/10.1093/schbul/sbaa062] [PMID: 32390043]
[20]
Goh, X.X.; Tang, P.Y.; Tee, S.F. Blood-based oxidation markers in medicated and unmedicated schizophrenia patients: A meta-analysis. Asian J. Psychiatr., 2022, 67, 102932.
[http://dx.doi.org/10.1016/j.ajp.2021.102932] [PMID: 34839098]
[21]
Addington, J.; el-Guebaly, N.; Campbell, W.; Hodgins, D.C.; Addington, D. Smoking cessation treatment for patients with schizophrenia. Am. J. Psychiatry, 1998, 155(7), 974-975.
[http://dx.doi.org/10.1176/ajp.155.7.974] [PMID: 9659869]
[22]
Zhang, X.Y.; Tan, Y.L.; Zhou, D.F.; Haile, C.N.; Wu, G.Y.; Cao, L.Y.; Kosten, T.A.; R Kosten, T. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology, 2007, 32(9), 2020-2024.
[http://dx.doi.org/10.1038/sj.npp.1301317] [PMID: 17228336]
[23]
Isik, B.; Ceylan, A.; Isik, R. Oxidative stress in smokers and non-smokers. Inhal. Toxicol., 2007, 19(9), 767-769.
[http://dx.doi.org/10.1080/08958370701401418] [PMID: 17613085]
[24]
Kay, S.R.; Fiszbein, A.; Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull., 1987, 13(2), 261-276.
[http://dx.doi.org/10.1093/schbul/13.2.261] [PMID: 3616518]
[25]
Correll, C.U.; Schooler, N.R. Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr. Dis. Treat., 2020, 16, 519-534.
[http://dx.doi.org/10.2147/NDT.S225643] [PMID: 32110026]
[26]
Fang, Y.; Wang, W.; Zhu, C.; Lin, G.N.; Cheng, Y.; Zou, J.; Cui, D. Use of tobacco in schizophrenia: A double‐edged sword. Brain Behav., 2019, 9(11), e01433.
[http://dx.doi.org/10.1002/brb3.1433] [PMID: 31605440]
[27]
Dalack, G.W.; Meador-Woodruff, J.H. Smoking, smoking withdrawal and schizophrenia: Case reports and a review of the literature. Schizophr. Res., 1996, 22(2), 133-141.
[http://dx.doi.org/10.1016/S0920-9964(96)80441-5] [PMID: 8958597]
[28]
Smith, R.; Singh, A.; Infante, M.; Khandat, A.; Kloos, A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology, 2002, 27(3), 479-497.
[http://dx.doi.org/10.1016/S0893-133X(02)00324-X] [PMID: 12225705]
[29]
Drew, A.E.; Derbez, A.E.; Werling, L.L. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse, 2000, 38(1), 10-16.
[http://dx.doi.org/10.1002/1098-2396(200010)38:1<10::AIDSYN2>3.0.CO;2-T] [PMID: 10941136]
[30]
Glassman, A.H. Cigarette smoking: Implications for psychiatric illness. Am. J. Psychiatry, 1993, 150(4), 546-553.
[http://dx.doi.org/10.1176/ajp.150.4.546] [PMID: 8465868]
[31]
Nomikos, G.G.; Schilström, B.; Hildebrand, B.E.; Panagis, G.; Grenhoff, J.; Svensson, T.H. Role of α7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav. Brain Res., 2000, 113(1-2), 97-103.
[http://dx.doi.org/10.1016/S0166-4328(00)00204-7] [PMID: 10942036]
[32]
Grenhoff, J.; Aston-Jones, G.; Svensson, T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand., 1986, 128(3), 351-358.
[http://dx.doi.org/10.1111/j.1748-1716.1986.tb07988.x] [PMID: 3788613]
[33]
Haslemo, T.; Eikeseth, P.H.; Tanum, L.; Molden, E.; Refsum, H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur. J. Clin. Pharmacol., 2006, 62(12), 1049-1053.
[http://dx.doi.org/10.1007/s00228-006-0209-9] [PMID: 17089108]
[34]
Rostami-Hodjegan, A.; Amin, A.M.; Spencer, E.P.; Lennard, M.S.; Tucker, G.T.; Flanagan, R.J. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J. Clin. Psychopharmacol., 2004, 24(1), 70-78.
[http://dx.doi.org/10.1097/01.jcp.0000106221.36344.4d] [PMID: 14709950]
[35]
Cooper, R.G. Effect of tobacco smoking on renal function. Indian J. Med. Res., 2006, 124(3), 261-268.
[PMID: 17085829]
[36]
Schoretsanitis, G.; Haen, E.; Stegmann, B.; Hiemke, C.; Gründer, G.; Paulzen, M. Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. Schizophr. Res., 2017, 185, 51-57.
[http://dx.doi.org/10.1016/j.schres.2016.12.016] [PMID: 27993531]
[37]
Sidle, E.H.; Casselman, R.; Smith, G.N. Effect of cigarette smoke on placental antioxidant enzyme expression. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 293(2), R754-R758.
[http://dx.doi.org/10.1152/ajpregu.00505.2006] [PMID: 17522121]
[38]
Rangasamy, T.; Cho, C.Y.; Thimmulappa, R.K.; Zhen, L.; Srisuma, S.S.; Kensler, T.W.; Yamamoto, M.; Petrache, I.; Tuder, R.M.; Biswal, S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke–induced emphysema in mice. J. Clin. Invest., 2004, 114(9), 1248-1259.
[http://dx.doi.org/10.1172/JCI200421146] [PMID: 15520857]
[39]
Bolzán, A.D.; Bianchi, M.S.; Bianchi, N.O. Superoxide dismutase, catalase and glutathione peroxidase activities in human blood: Influence of sex, age and cigarette smoking. Clin. Biochem., 1997, 30(6), 449-454.
[http://dx.doi.org/10.1016/S0009-9120(97)00047-7] [PMID: 9316738]
[40]
Ho, S.P.; Chan-Yeung, M.; Chow, K.K.M.; Ip, M.S.M.; Mak, J.C.W. Antioxidant enzyme activities in healthy Chinese adults: Influence of age, gender and smoking. Respirology, 2005, 10(3), 305-309.
[http://dx.doi.org/10.1111/j.1440-1843.2005.00702.x] [PMID: 15955142]
[41]
Brigelius-Flohé, R. Tissue-specific functions of individual glutathione peroxidases. Free Radic. Biol. Med., 1999, 27(9-10), 951-965.
[http://dx.doi.org/10.1016/S0891-5849(99)00173-2] [PMID: 10569628]
[42]
Chen, N.; Liu, H.; Yao, J.; Chen, S.; Xiu, M.; Wu, F.; Zhang, X. Smoke, GPx activity and symptoms improvement in patients with drug-naive first-episode schizophrenia: A large-scale 12-week follow-up study. Asian J. Psychiatr., 2022, 77, 103267.
[http://dx.doi.org/10.1016/j.ajp.2022.103267] [PMID: 36202003]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy